The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]
Some individuals may experience mild digestive discomfort or skin rashes
PlexusDx offers Compounded Tirzepatide Injection at $289/mo month-to-month, or from $249/mo on the 6-month plan, plus combination GLP-Squared products for those seeking dual-pathway support
Overall, I felt like my body was working with me, not against me
10.1056/NEJM199205143262003 16
Some studies indicate that the risk is also due to higher homocysteine levels[ref], while other studies show that it may be due to the methylation of certain genes.[ref] Meta-analyses showed that the MTHFR C677T variant increased the risk of migraines with aura for all population ancestry groups